

ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS

Ye Miao

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

In ulcerative colitis patients treated with ustekinumab, achieving both histo-endoscopic mucosal improvement and symptomatic remission after induction predicts superior long-term outcomes through 4 years compared to achieving symptomatic remission alone or neither endpoint.

KEY POINTS

- Patients with disease clearance (both HEMI and symptomatic remission) at 8 weeks maintained symptomatic remission rates of 73.4% at week 200, compared to 53.5% for those with symptomatic remission without HEMI and 45.1% for those with neither.
- Time to treatment failure (UC-related surgery, hospitalization, or discontinuation) was significantly longer in the disease clearance group versus symptomatic remission without HEMI ($p=0.004$), and in symptomatic remission without HEMI versus neither ($p=0.043$).
- This long-term extension of the UNIFI trial categorized 79 patients as disease clearance, 142 as symptomatic remission without HEMI, and 82 as neither at 8 weeks post-induction.
- HEMI was defined as less than 5% neutrophils in epithelium, no crypt destruction, no erosions/ulcerations/granulations, and Mayo endoscopic subscore of 0 or 1; symptomatic remission required stool frequency subscore 0 or 1 and rectal bleeding subscore 0.
- This analysis may inform treat-to-target strategies in ulcerative colitis by identifying early combined mucosal and symptomatic endpoints that predict durable disease control.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/a6138300-743b-11ee-a5b5-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.